McKesson Corporation(MCK)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest News & Analysis
McKesson's (MCK) PRISM Acquisition: Strategic Financial Impact
McKesson's acquisition of PRISM Vision Holdings strategically expands into ophthalmology, promising EPS growth and market leadership amidst evolving healthcare dynamics.
McKesson (MCK): Analyst Optimism, GLP-1 Growth, and Defensive Stock Strategy
McKesson (MCK) navigates market volatility with analyst optimism, driven by GLP-1 growth and strategic acquisitions. A defensive stock with dividend growth potential.
McKesson (MCK): GLP-1 Growth, Strategic Acquisitions & Challenges
McKesson navigates healthcare's complexities with strategic acquisitions and GLP-1 demand, balancing growth with financial stability amid regulatory and economic challenges.
McKesson (MCK) Q3 2025 Earnings: Challenges and Growth Ahead
McKesson's Q3 2025 earnings reveal strategic shifts amid challenges like gross margin contraction and declining COVID-related sales. A deep dive into MCK's resilience and growth prospects.
McKesson (MCK) Analysis: Q3 2025 Results, PRISM Acquisition
In-depth analysis of McKesson's Q3 2025 results, PRISM Vision acquisition, and market outlook. Key takeaways for investors and strategic implications.
McKesson (MCK): Q3 2025 Earnings, Market Trends, and Future Outlook
McKesson Corporation (MCK) faces mixed Q3 2025 results, but strategic growth in pharmaceuticals and RxTS offers a promising outlook. Dividend declared.
McKesson (MCK) Analysis: Q3 Earnings, Oncology Strategy, and Future Outlook
A comprehensive analysis of McKesson Corporation (MCK), including Q3 earnings, strategic initiatives, analyst estimates, and macroeconomic factors. A balanced outlook for investors.
McKesson (MCK) Q3 2025 Earnings Analysis: Challenges and Opportunities
McKesson's Q3 2025 earnings reveal a mixed performance amid macroeconomic challenges. Strategic initiatives and investor sentiment shape the future outlook.
McKesson (MCK) Q3 2025 Earnings: Revenue Misses, EPS Beats, and Revised Guidance
McKesson's Q3 Fiscal 2025 results present a mixed picture: EPS beats expectations, but revenue falls short, prompting a deeper look into strategic moves and market dynamics.
McKesson (MCK) Q3 2025 Earnings: Challenges and Opportunities
McKesson's Q3 2025 reveals mixed performance with EPS beat but revenue miss. Focus shifts to strategic initiatives and market adaptation.
McKesson Q3 2025: Earnings Beat Masks Revenue Concerns
McKesson’s Q3 2025 earnings surpassed EPS targets despite a revenue miss, highlighting segmented growth and evolving market challenges.
McKesson Corporation Announces Major Business Developments | Latest Industry News
McKesson Corporation's latest news: Q3 earnings analysis, strategic shifts, and market impact. Stay informed with real-time data and expert insights.